A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Part of paid clinical trials in Yuma, Arizona.

Sponsor
Eli Lilly and Company
Study ID
NCT06901349
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

Key Dates

Start date
May 23, 2025
Status verified
Sep 2025
Primary completion
Jun 10, 2025
Completion
Jun 10, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bimagrumab Dose 1 + Tirzepatide Placebo
    Participants will receive bimagrumab subcutaneously (SC) and tirzepatide placebo SC
  • Experimental: Bimagrumab Dose 2 + Tirzepatide Placebo
    Participants will receive bimagrumab SC and tirzepatide placebo SC
  • Experimental: Tirzepatide Dose 1 + Bimagrumab Placebo
    Participants will receive tirzepatide SC and bimagrumab placebo SC
  • Experimental: Tirzepatide Dose 2 + Bimagrumab Placebo
    Participants will receive tirzepatide SC and bimagrumab placebo SC
  • Experimental: Bimagrumab Dose 2 + Tirzepatide Dose 1
    Participants will receive bimagrumab SC and tirzepatide SC
  • Experimental: Bimagrumab Dose 1 + Tirzepatide Dose 1
    Participants will receive bimagrumab SC and tirzepatide SC
  • Experimental: Bimagrumab Dose 2 + Tirzepatide Dose 2
    Participants will receive bimagrumab SC and tirzepatide SC
  • Experimental: Bimagrumab Dose 1 + Tirzepatide Dose 2
    Participants will receive bimagrumab SC and tirzepatide SC
  • Placebo Comparator: Bimagrumab Placebo + Tirzepatide Placebo
    Participants will receive bimagrumab placebo SC and tirzepatide placebo SC

Primary Outcome Measure

Percent Change from Baseline in Body Weight [ Time Frame: Baseline, Week 36 ]

Locations (25)

FacilityCityStateZIPSite coordinators
Yuma Clinical TrialsYumaArizona85364-
Orange County Research CenterLake ForestCalifornia92630-
Healthy Brain ClinicLong BeachCalifornia90804-
Valley Clinical Trials, Inc.NorthridgeCalifornia91325-
Diablo Clinical Research, Inc.Walnut CreekCalifornia94598-
Excel Medical Clinical TrialsBoca RatonFlorida33434-
Clinical Neuroscience Solutions, Inc. dba CNS HealthcareJacksonvilleFlorida32256-
L&C Professional Medical Research InstituteMiamiFlorida33144-
Global Health Research Center, Inc.Miami LakesFlorida33016-
Charter Research - Winter ParkOrlandoFlorida32803-
Charter Research - Lady LakeThe VillagesFlorida32162-
Balanced Life Health Care Solutions/SKYCRNGLawrencevilleGeorgia30046-
East-West Medical Research InstituteHonoluluHawaii96814-
Bingham Memorial HospitalBlackfootIdaho83221-
Family First Medical CenterIdaho FallsIdaho83404-
Deaconess Clinic- GatewayNewburghIndiana47630-
Kur Research - Columbia MedicalColumbiaMaryland21045-
Great Lakes Research Group, Inc.Bay CityMichigan48706-
University of North Carolina Medical CenterChapel HillNorth Carolina27514-
Remington-Davis, IncColumbusOhio43215-
Central States ResearchTulsaOklahoma74136-
Velocity Clinical Research, DallasDallasTexas75230-
PlanIt Research, PLLCHoustonTexas77079-
Activian Clinical ResearchKingwoodTexas77339-
Northwest Clinical Research CenterBellevueWashington98007-

Find similar trials in Yuma, AZ

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Yuma Clinical Trials· Yuma, AZOrange County Research Center· Lake Forest, CAHealthy Brain Clinic· Long Beach, CAValley Clinical Trials, Inc.· Northridge, CADiablo Clinical Research, Inc.· Walnut Creek, CAExcel Medical Clinical Trials· Boca Raton, FL

Related Studies